Fig. 1.
Baseline serum IL-6 levels are higher in patients without clinical benefit than in those with clinical benefit. (A) Comparisons of baseline serum cytokine levels, laboratory markers, and clinical characteristics. (B) Comparisons of baseline serum IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α levels according to CB6m (CB6m, n = 47; non-CB6m, n = 37). (C) Comparisons of serum IL-6 levels according to the best response. Values were compared using unpaired t tests (B) or ANOVA with Tukey’s post hoc test (C). CB6m, clinical benefit 6 months; CR, complete response; IFN-γ, interferon-γ; NLR, neutrophil-to-lymphocyte ratio; PD, progressive disease; PFS, progression-free survival; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; PR, partial response; PVT, portal vein thrombosis; SD, stable disease; SII, systemic immune-inflammation index; TNF-α, tumour necrosis factor-α.